Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting
April 02, 2017 13:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics Announces Executive Changes
March 20, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing...
Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results
February 23, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23
February 09, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...
Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
February 08, 2017 16:10 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting
February 08, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS)
January 24, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that the European Commission has granted orphan designation for...
Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
January 04, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 03, 2017 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Presents Data from FPA144 in Urothelial Cancer at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapies
December 01, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...